Comments
Loading...
Avalo Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:AVTX | Benzinga
Avalo Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Nov 7
EPS
$-2.830
Quarterly Revenue
$249.00K
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$441.00K
Analyze the earnings history of Avalo Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics | -$6.11 | — | — | — | $0.00 | — | — | — | 05/12/2025 | Get Alert |
| AVTX | Avalo Therapeutics | -$10.12 | — | — | — | $571.00K | — | — | — | 04/15/2025 | Get Alert |
| AVTX | Avalo Therapeutics | -$26.40 | -$1.45 | -$2.83 | -95.17% | $236.00K | — | $249.00K | — | 11/07/2024 | Get Alert |
| AVTX | Avalo Therapeutics | -$141.60 | -$6.70 | -$14.07 | -110.00% | $643.00K | — | $0.00 | — | 08/12/2024 | Get Alert |
| AVTX | Avalo Therapeutics | -$204.00 | -$1.18 | -$6.11 | -417.80% | $475.00K | — | $0.00 | — | 05/13/2024 | Get Alert |
| AVTX | Avalo Therapeutics | -$249.60 | -$4.80 | -$10.12 | -110.83% | $896.00K | $300.00K | $571.00K | 90.33% | 03/29/2024 | Get Alert |
| AVTX | Avalo Therapeutics | $81.60 | -$264.00 | -$26.40 | 90.00% | $14.95M | $1.00M | $236.00K | -76.40% | 11/09/2023 | Get Alert |
| AVTX | Avalo Therapeutics | -$331.20 | -$192.00 | -$141.60 | 26.25% | $1.03M | $500.00K | $643.00K | 28.60% | 08/03/2023 | Get Alert |
| AVTX | Avalo Therapeutics | -$576.00 | -$232.80 | -$204.00 | 12.37% | $1.17M | $1.00M | $475.00K | -52.50% | 05/04/2023 | Get Alert |
| AVTX | Avalo Therapeutics | -$460.80 | -$175.20 | -$249.60 | -42.47% | $219.00K | $3.61M | $896.00K | -75.18% | 03/29/2023 | Get Alert |
| AVTX | Avalo Therapeutics | -$499.20 | -$261.60 | $81.60 | 131.19% | $1.35M | $1.08M | $14.95M | 1284.17% | 11/07/2022 | Get Alert |
| AVTX | Avalo Therapeutics | -$2.16 | -$424.80 | -$331.20 | 22.03% | $3.35M | $790.00K | $1.03M | 30.76% | 08/04/2022 | Get Alert |
| AVTX | Avalo Therapeutics | -$3.84 | -$374.40 | -$576.00 | -53.85% | $473.00K | $370.00K | $1.17M | 217.03% | 05/05/2022 | Get Alert |
| AVTX | Avalo Therapeutics | -$2.28 | — | -$460.80 | — | $1.50M | — | $219.00K | — | 03/02/2022 | Get Alert |
| AVTX | Avalo Therapeutics | -$1.92 | -$518.40 | -$489.60 | 5.56% | $1.11M | $1.12M | $1.35M | 20.54% | 11/09/2021 | Get Alert |
| AVTX | Avalo Therapeutics | -$2.16 | -$1.92 | -$2.16 | -12.50% | $1.34M | $4.20M | $3.35M | -20.12% | 08/02/2021 | Get Alert |
| AVTX | Avalo Therapeutics | -$4.32 | -$1.92 | -$3.84 | -100.00% | $2.75M | $4.20M | $473.00K | -88.74% | 05/13/2021 | Get Alert |
| AVTX | Avalo Therapeutics | -$1.20 | — | -$2.28 | — | $3.44M | — | $1.50M | — | 03/08/2021 | Get Alert |
| AVTX | Avalo Therapeutics | -$0.84 | — | -$1.92 | — | $5.61M | — | $1.11M | — | 11/09/2020 | Get Alert |
| AVTX | Avalo Therapeutics | -$1.32 | — | -$2.16 | — | $4.45M | — | $1.34M | — | 08/06/2020 | Get Alert |
| AVTX | Avalo Therapeutics | -$1.56 | — | -$4.32 | — | $5.41M | — | $2.75M | — | 05/07/2020 | Get Alert |
Avalo Therapeutics (AVTX) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | 2024-11-07 | $-2.83 | $-1.45 | -95.2 % |
| Q2 | 2024-08-12 | $-14.07 | $-6.70 | -110.0 % |
| Q1 | 2024-05-13 | $-6.11 | $-1.18 | -417.8 % |
| Q4 | 2024-03-29 | $-10.12 | $-4.80 | -110.8 % |
Avalo Therapeutics (AVTX) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2024-03-29 | $571.00K | $300.00K | 90.3 % |
| Q3 | 2023-11-09 | $236.00K | $1.00M | -76.4 % |
| Q2 | 2023-08-03 | $643.00K | $500.00K | 28.6 % |
| Q1 | 2023-05-04 | $475.00K | $1.00M | -52.5 % |
FAQ
When is Avalo Therapeutics (NASDAQ:AVTX) reporting earnings?
Avalo Therapeutics (AVTX) is scheduled to report earnings on May 12, 2025. The last reported earnings were for reported on November 7, 2024 for Q3.
What were the latest earnings per share (EPS) for Avalo Therapeutics (NASDAQ:AVTX)?
The Actual EPS was $-2.83, which missed the estimate of $-1.45.
What were Avalo Therapeutics’s (NASDAQ:AVTX) revenues?
The Actual Revenue was $249K, which beat the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.